Your browser doesn't support javascript.
loading
Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome.
Grob, Tim; Al Hinai, Adil S A; Sanders, Mathijs A; Kavelaars, François G; Rijken, Melissa; Gradowska, Patrycja L; Biemond, Bart J; Breems, Dimitri A; Maertens, Johan; van Marwijk Kooy, Marinus; Pabst, Thomas; de Weerdt, Okke; Ossenkoppele, Gert J; van de Loosdrecht, Arjan A; Huls, Gerwin A; Cornelissen, Jan J; Beverloo, H Berna; Löwenberg, Bob; Jongen-Lavrencic, Mojca; Valk, Peter J M.
Affiliation
  • Grob T; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Al Hinai ASA; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Sanders MA; National Genetic Center, Royal Hospital, Ministry of Health, Muscat, Sultanate of Oman.
  • Kavelaars FG; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Rijken M; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Gradowska PL; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Biemond BJ; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Breems DA; Department of Hematology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
  • Maertens J; Department of Hematology, Ziekenhuis Netwerk Antwerpen, Antwerp, Belgium.
  • van Marwijk Kooy M; Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium.
  • Pabst T; Department of Hematology, Isala Hospital, Zwolle, The Netherlands.
  • de Weerdt O; Department of Oncology, University Hospital, Inselspital, Bern, Switzerland.
  • Ossenkoppele GJ; Department of Hematology, Saint Antonius Hospital, Nieuwegein, The Netherlands.
  • van de Loosdrecht AA; Department of Hematology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
  • Huls GA; Department of Hematology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
  • Cornelissen JJ; Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands; and.
  • Beverloo HB; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Löwenberg B; Department of Clinical Genetics, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Jongen-Lavrencic M; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
  • Valk PJM; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Blood ; 139(15): 2347-2354, 2022 04 14.
Article in En | MEDLINE | ID: mdl-35108372
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Myelodysplastic Syndromes / Leukemia, Myeloid, Acute Type of study: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Blood Year: 2022 Document type: Article Affiliation country: Países Bajos Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Myelodysplastic Syndromes / Leukemia, Myeloid, Acute Type of study: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Blood Year: 2022 Document type: Article Affiliation country: Países Bajos Country of publication: Estados Unidos